Reports
Reports
Sale
The global heparin market size was valued at USD 9.08 billion in 2023, driven by the growing prevalence of cardiovascular and other chronic disorders across the globe. The market is expected to grow at a CAGR of 4.41% during the forecast period of 2024-2032, with the values likely to rise from USD 9.48 billion in 2024 to USD 13.38 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Heparin is an anticoagulant used to treat and prevent the formation of blood clots. Heparin cannot be absorbed via the digestive system, so it is taken intravenously or injected below the skin. Heparin drugs work by making thrombin (a coagulation factor) inactive, preventing clot formation in the blood. Heparin is used for certain medical conditions such as venous thromboembolism (VTE), deep vein thrombosis (DVT), heart attack, or after a medical procedure like heart surgery.
The heparin market growth is driven by the increasing prevalence of cardiovascular diseases, which is poised to fuel the demand for anticoagulant products. Venous thromboembolism (VTE), characterized by the formation of a blood clot in the veins, and affects 1 in 12 individuals in the western region, with 20% of affected individuals dying within an year of diagnosis. As a result, there is a high demand for anticoagulants and is expected to increase in the forecast period. In addition, growth in healthcare expenditure and rising patient awareness are some of the key factors poised to accelerate the market growth in coming years.
Increased Approval for Heparin Drugs by Regulatory Bodies
The surge in drug approvals by health authorities such as the United States Food and Drug Administration (FDA) along with the increased use of heparin in various drug formulations is projected to increase the heparin market share in the coming years. In November 2023 , the FDA approved DefenCath, a formulation of taurolidine and heparin, developed by a United States-based biopharmaceutical company CorMedix Inc. The therapeutic product DefenCath is an antimicrobial catheter lock solution that reduces catheter-related bloodstream infections (CRBSIs) by 71% in adult hemodialysis patients. The approval is based on the positive results from the phase 3 LOCK IT-100 trial.
Rise in Product Launches to Meet the Rising Heparin Market Demand
In June 2023 , Techdow USA Inc., a pharmaceutical company announced the launch of generic Enoxaparin Sodium (Preservative Free) Prefilled Syringes, a low molecular weight heparin (LMWH). Available at different strengths such as 30mg, 100mg, and 150mg, the drug prevents the formation of blood clots in various medical conditions. The U.S. FDA granted the final approval of the Abbreviated New Drug Application for the product as well. The commercial release and approval of such products indicate the commitment of the key market players to meet the rising demand for heparin.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Products
Breakup by Source
Market Breakup by Applications
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America accounts for the largest share of the heparin market which can be attributed to the increasing prevalence of cardiovascular diseases in the region. According to the data released by the American Heart Association , cardiovascular diseases stand as the leading cause of death in the United States. Heparin, as an anticoagulant, plays a crucial role in treating and managing cardiovascular conditions and thus, has a significant demand in the region. In addition, the growth of the market is propelled by the presence of the key market players and robust support from the government.
Asia Pacific also holds a significant heparin market share and is anticipated to witness rapid growth in the coming years. The major key drivers are the rising patient awareness and disease burden. Furthermore, technological advancements and intensive research and development activities to improve the healthcare system are expected to accelerate the market growth. In May 2023 , a team of researchers at the Thailand Excellence Center for Tissue Engineering and Stem Cells, Department of Biochemistry from Chiang Mai University discovered an alternative source of heparin. They extracted acharan sulfate (heparin-like substances) from the mucus of the giant African snail, Achatina fulica, which has the potential to address the rising demand for the essential anticoagulant.
In November 2023 , a multinational Danish pharmaceutical company, Leo Pharma, announced a cooperation agreement with a Greek pharmaceutical company, Vianex SA. Under the terms of agreement, Vianex will be responsible for manufacturing low molecular weight heparin and unfractionated heparin. On the other hand, Leo Pharma will handle the distribution of the final product. The production of five product codes is estimated to amount to several million vials per year. The objective of the collaboration is to increase their market presence and expand the distribution of their products in over 23 countries. This indicates a market trend of increasing collaborations among the leading market players to boost their manufacturing capacity. Consequently, this will fuel the heparin market share in the forecast period.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Products |
|
Breakup by Source |
|
Breakup by Applications |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Heparin Market (2017-2032) Overview
3.1 Global Heparin Market (2017-2032) Historical Value (2017-2023)
3.2 Global Heparin Market (2017-2032) Forecast Value (2024-2032)
4 Global Heparin Market (2017-2032) Landscape*
4.1 Global Heparin Market (2017-2032): Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Heparin Market (2017-2032): Product Landscape
4.2.1 Analysis by Products
4.2.2 Analysis by Applications
5 Global Heparin Market (2017-2032) Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Heparin Market (2017-2032) Segmentation
6.1 Global Heparin Market (2017-2032) by Products
6.1.1 Market Overview
6.1.2 Unfractionated Heparin
6.1.3 Low Molecular Weight Heparin (LMWH)
6.1.4 Ultra-Low Molecular Weight Heparin (ULMWH)
6.2 Global Heparin Market (2017-2032) by Source
6.2.1 Market Overview
6.2.2 Bovine
6.2.3 Porcine
6.3 Global Heparin Market (2017-2032) by Applications
6.3.1 Market Overview
6.3.2 Deep Vein Thrombosis (DVT)
6.3.3 Atrial Fibrillation and Heart Attack
6.3.4 Coronary Artery Disease
6.3.5 Other Applications
6.4 Global Heparin Market (2017-2032) by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Heparin Market (2017-2032)
7.1 North America Heparin Market (2017-2032) by Products
7.1.1 Market Overview
7.1.2 Unfractionated Heparin
7.1.3 Low Molecular Weight Heparin (LMWH)
7.1.4 Ultra-Low Molecular Weight Heparin (ULMWH)
7.2 North America Heparin Market (2017-2032) by Sources
7.2.1 Market Overview
7.2.2 Bovine
7.2.3 Porcine
7.3 North America Heparin Market(2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Heparin Market (2017-2032)
8.1 Europe Heparin Market(2017-2032) by Products
8.1.1 Market Overview
8.1.2 Unfractionated Heparin
8.1.3 Low Molecular Weight Heparin (LMWH)
8.1.4 Ultra-Low Molecular Weight Heparin (ULMWH)
8.2 Europe Heparin Market (2017-2032) by Sources
8.2.1 Market Overview
8.2.2 Bovine
8.2.3 Porcine
8.3 Europe Heparin Market (2017-2032) (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Heparin Market (2017-2032)
9.1 Asia Pacific Heparin Market(2017-2032) by Products
9.1.1 Market Overview
9.1.2 Unfractionated Heparin
9.1.3 Low Molecular Weight Heparin (LMWH)
9.1.4 Ultra-Low Molecular Weight Heparin (ULMWH)
9.2 Asia Pacific Heparin Market (2017-2032) by Sources
9.2.1 Market Overview
9.2.2 Bovine
9.2.3 Porcine
9.3 Asia Pacific Heparin Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 ASEAN
9.3.6 Others
10 Latin America Heparin Market (2017-2032)
10.1 Latin America Heparin Market (2017-2032) by Products
10.1.1 Market Overview
10.1.2 Unfractionated Heparin
10.1.3 Low Molecular Weight Heparin (LMWH)
10.1.4 Ultra-Low Molecular Weight Heparin (ULMWH)
10.2 Latin America Heparin Market (2017-2032) by Sources
10.2.1 Market Overview
10.2.2 Bovine
10.2.3 Porcine
10.3 Latin America Heparin Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Heparin Market (2017-2032)
11.1 Middle East and Africa Heparin Market (2017-2032) by Products
11.1.1 Market Overview
11.1.2 Unfractionated Heparin
11.1.3 Low Molecular Weight Heparin (LMWH)
11.1.4 Ultra-Low Molecular Weight Heparin (ULMWH)
11.2 Middle East and Africa Heparin Market(2017-2032) by Sources
11.2.1 Market Overview
11.2.2 Bovine
11.2.3 Porcine
11.3 Middle East and Africa Heparin Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Aspen Pharmacare Holdings Limited
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 B Braun Melsungen AG
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Baxter International
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Dr. Reddy's Laboratories
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Hebei Changshan Biochemical Pharmaceutical
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Leo Pharma AS
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Opocrin SpA
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Pfizer Inc
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Techdow USA
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Viatris Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Novartis AG
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Aspen Oss
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Leo Pharma A/S
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Hikma Pharmaceuticals PLC
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 Sanofi
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
List not exhaustive
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The market attained a value of about USD 9.08 billion in 2023 driven by the growing prevalence of cardiovascular and other chronic disorders across the globe.
The market is anticipated to grow at a CAGR of 4.41% during the forecast period of 2024-2032, likely to reach a market value of USD 13.38 billion by 2032.
The increased expenditure on healthcare and the rising patient awareness are some of the factors contributing to the market demand.
The high demand for anticoagulants and the growing use of heparin in various drug formulations are the major trends driving the heparin market. In November 2023, the FDA approved DefenCath, a formulation of taurolidine and heparin, developed by CorMedix Inc. It is an antimicrobial catheter lock solution that reduces catheter-related bloodstream infections (CRBSIs) by 71% in adult hemodialysis patients.
The various products in the market are unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH).
Based on the source, the market is segmented into bovine and porcine.
Application areas of heparin include deep vein thrombosis (DVT), atrial fibrillation & heart attack, and coronary artery disease, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Aspen Pharmacare Holdings Limited, B Braun Melsungen AG, Baxter International, Dr. Reddy's Laboratories, Hebei Changshan Biochemical Pharmaceutical, Leo Pharma AS, Opocrin SpA, Pfizer Inc, Techdow USA, Viatris Inc., Novartis AG, Aspen Oss, Leo Pharma A/S, Hikma Pharmaceuticals PLC, and Sanofi.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.